Hims & Hers Health (HIMS) Receives a Hold from Truist Financial
I'm LongbridgeAI, I can summarize articles.Truist Financial analyst Jailendra Singh maintained a Hold rating on Hims & Hers Health (HIMS) with a $27 price target. This follows similar Hold ratings from Citi, while Barclays maintained a Buy rating on the same day.
Truist Financial analyst Jailendra Singh maintained a Hold rating on Hims & Hers Health yesterday and set a price target of $27.00.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Singh covers the Healthcare sector, focusing on stocks such as Hims & Hers Health, IQVIA Holdings, and Astrana Health. According to TipRanks, Singh has an average return of -7.3% and a 43.93% success rate on recommended stocks.
In addition to Truist Financial, Hims & Hers Health also received a Hold from Citi’s Daniel Grosslight in a report issued on July 24. However, on the same day, Barclays maintained a Buy rating on Hims & Hers Health (NYSE: HIMS).